Pfizer's Non-Oncology Portfolio Carries the Quarter While Everyone Watches Something Else
Pfizer Inc. (NYSE: PFE) reports first-quarter 2026 earnings before market open on Monday, May 5, with analysts expecting $0.71 per share on revenue that remains to be seen. The pharmaceutical giant faces a critical test as investors assess whether its post-pandemic portfolio can sustain growth amid declining COVID-related revenues and mounting pressure on its core therapeutic franchises. With the stock trading at $26.30 and consensus estimates pointing to a sharp year-over-year decline, this report will either validate management's transformation strategy or deepen concerns about the company's near-term trajectory.
Part 1: Earnings Preview
Pfizer Inc. is a global biopharmaceutical company headquartered in New York, focused on discovering, developing, manufacturing, and distributing innovative medicines and vaccines across oncology, internal medicine, rare diseases, inflammation & immunology, anti-infectives, and vaccines. As one of the world's largest healthcare companies, Pfizer's performance serves as a bellwether for the pharmaceutical sector and directly impacts millions of patients worldwide.
Pfizer reports Q1 2026 earnings on May 5, 2026, before market open, with the consensus estimate calling for $0.71 per share. This represents a significant decline from the $0.66 per share the company reported in Q4 2025 and marks a steep 22.83% drop from the $0.92 earned in Q1 2025. The year-over-year comparison underscores the challenge Pfizer faces as COVID-19 product revenues continue their structural decline.
Three key themes define this earnings story:
Post-Pandemic Revenue Sustainability: Investors are laser-focused on whether Pfizer can offset the ongoing erosion of Paxlovid and Comirnaty (COVID-19 vaccine) sales with growth from its base business. Management's ability to demonstrate durable revenue streams beyond pandemic products will be critical to restoring confidence in the company's long-term earnings power.
Pipeline Progress and New Product Launches: With patent expirations looming on several legacy blockbusters, Pfizer's R&D pipeline and recent product launches take center stage. Analysts are watching for updates on regulatory approvals, clinical trial progress, and early commercial traction for newer therapies that could drive the next growth cycle.
Operational Efficiency and Margin Management: As revenues face headwinds, Pfizer's ability to control costs and maintain profitability becomes paramount. Investors will scrutinize gross margin trends, operating expense discipline, and any commentary on restructuring initiatives or strategic acquisitions that could reshape the cost structure.
Ahead of the release, analyst commentary reflects cautious optimism tempered by near-term uncertainty. While some analysts point to Pfizer's diversified portfolio and strong free cash flow generation as reasons to remain constructive, others emphasize the magnitude of the COVID revenue cliff and question whether the company's guidance adequately reflects the challenges ahead. The consensus holds at a neutral stance, with the market awaiting concrete evidence that Pfizer's transformation is gaining traction.
Part 2: Historical Earnings Performance
Pfizer has established a consistent pattern of exceeding analyst expectations, delivering positive earnings surprises in each of the past four quarters. In Q1 2025, the company reported $0.92 per share against a $0.64 estimate, representing a substantial +43.75% beat. Q2 2025 saw another strong performance with $0.78 versus $0.58 expected (+34.48%), followed by Q3's $0.87 against $0.66 (+31.82%). Most recently, Q4 2025 came in at $0.66 versus $0.57, a more modest but still meaningful +15.79% surprise.
The trend reveals a company that has consistently outperformed lowered expectations, though the magnitude of the beats has moderated over time. The Q4 surprise of 15.79% marked the smallest upside in the four-quarter sequence, suggesting either that analysts are calibrating their models more accurately or that Pfizer's ability to exceed estimates is normalizing as the business stabilizes post-pandemic. Notably, the absolute EPS figures have declined sequentially from $0.92 in Q1 2025 to $0.66 in Q4 2025, reflecting the structural headwinds from declining COVID product sales even as the company continues to beat estimates.
This track record of positive surprises provides some cushion heading into Monday's report, though investors should note that beating a significantly reduced estimate may not be sufficient to drive the stock higher if the underlying business trends or forward guidance disappoint. The pattern suggests Pfizer has been managing expectations effectively, but the real test will be whether the company can demonstrate stabilization in its core business and provide a credible path to renewed growth.
| Quarter | EPS Estimate | EPS Actual | Surprise % | Beat/Miss |
|---|---|---|---|---|
| Mar 2025 | $0.64 | $0.92 | +43.75% | Beat |
| Jun 2025 | $0.58 | $0.78 | +34.48% | Beat |
| Sep 2025 | $0.66 | $0.87 | +31.82% | Beat |
| Dec 2025 | $0.57 | $0.66 | +15.79% | Beat |
Note: These figures reflect diluted GAAP earnings per share, reported before non-recurring items, and may differ from the non-GAAP figures used by some sources.
Part 2.1: Price Behavior Around Earnings
Pfizer typically reports earnings before market open, meaning Day 0 represents the first full trading session where investors react to results, while Day +1 captures follow-through momentum.
| Earnings Date | Day 0 Move | Day 0 Range | Day +1 Move | Day +1 Range |
|---|---|---|---|---|
| 2026-02-03 | -$0.89 (-3.34%) | $0.84 (3.17%) | +$1.01 (+3.92%) | $1.12 (4.35%) |
| 2025-11-04 | -$0.36 (-1.46%) | $1.00 (4.06%) | +$0.31 (+1.28%) | $0.51 (2.10%) |
| 2025-08-05 | +$1.22 (+5.18%) | $0.62 (2.63%) | -$0.82 (-3.31%) | $0.85 (3.43%) |
| 2025-04-29 | +$0.74 (+3.21%) | $1.66 (7.20%) | +$0.62 (+2.61%) | $0.46 (1.93%) |
| 2025-02-04 | -$0.33 (-1.26%) | $1.32 (5.03%) | +$0.57 (+2.20%) | $0.99 (3.83%) |
| 2024-10-29 | -$0.40 (-1.39%) | $1.15 (3.97%) | +$0.06 (+0.21%) | $0.41 (1.44%) |
| 2024-07-30 | +$0.67 (+2.18%) | $1.76 (5.73%) | -$0.85 (-2.71%) | $0.79 (2.52%) |
| 2024-05-01 | +$1.56 (+6.09%) | $1.43 (5.58%) | +$0.52 (+1.91%) | $0.82 (3.02%) |
| Avg Abs Move | 3.01% | 4.67% | 2.27% | 2.83% |
Pfizer's post-earnings price behavior shows moderate volatility with no consistent directional bias. Over the past eight quarterly reports, the stock has averaged an absolute move of 3.01% on Day 0 with an intraday range of 4.67%, followed by a 2.27% average absolute move on Day +1 with a 2.83% range. The most recent report on February 3, 2026, saw the stock decline 3.34% on Day 0 before rebounding 3.92% on Day +1, illustrating the two-way volatility that often characterizes Pfizer's earnings reactions.
The historical data reveals no clear pattern of sustained upside or downside following earnings—moves have been roughly balanced between gains and losses, with the magnitude varying considerably from quarter to quarter. The largest Day 0 move in the sample was a 6.09% gain on May 1, 2024, while the most recent quarter's 3.34% decline was among the more pronounced negative reactions. Investors should prepare for a potential swing in the 3-5% range based on historical norms, with the direction likely determined by whether results and guidance exceed, meet, or fall short of the market's expectations beyond the published consensus.
Part 2.2: Options Market Expected Move
| Metric | Value |
|---|---|
| Expiration Date | 05/08/26 (DTE 4) |
| Expected Move | $0.99 (3.78%) |
| Expected Range | $25.31 to $27.29 |
| Implied Volatility | 51.32% |
The options market is pricing an expected move of 3.78% through the May 8 weekly expiration, which sits slightly above the historical average Day 0 move of 3.01% but below the average intraday range of 4.67%. This suggests options traders are anticipating a typical earnings reaction rather than an outsized move, though the implied volatility of 51.32% indicates elevated uncertainty heading into the release.
Part 3: What Analysts Are Saying
Analysts maintain a cautious stance on Pfizer, with the consensus rating sitting at 3.39 out of 5.0—squarely in Hold territory. The average price target of $29.09 implies 10.6% upside from the current price of $26.30, though the wide range of targets from a low of $24.00 to a high of $36.00 reflects significant disagreement about the stock's fair value.
The breakdown of the 28 analysts covering Pfizer shows a divided Street: 8 Strong Buys and 1 Moderate Buy on the bullish side, 16 Holds in the middle, and 3 Strong Sells expressing bearish views. Notably, the lack of any Moderate Sell ratings suggests analysts are either constructive, neutral, or outright negative—with little middle ground among the bears.
Sentiment has remained unchanged over the past month, with the rating distribution and average recommendation holding steady at 3.39. This stability suggests analysts are in wait-and-see mode ahead of Monday's report, with no recent catalysts prompting meaningful upgrades or downgrades. The consensus appears to be that Pfizer's valuation is reasonable at current levels, but the stock needs to demonstrate tangible progress on its post-pandemic growth strategy to justify a more bullish stance.
The modest implied upside to the average target, combined with the neutral rating, indicates the Street views Pfizer as fairly valued with limited near-term catalysts absent a significant positive surprise on earnings or guidance. Investors looking for conviction will need to see this report shift the narrative.
Part 4: Technical Picture
Pfizer enters earnings with a deteriorating technical picture that has weakened considerably in recent weeks. The Barchart Technical Opinion currently registers a Buy signal at 24%, down sharply from 56% Buy one week ago and 100% Buy one month ago. This rapid erosion in technical strength suggests momentum has stalled and the stock is losing its footing heading into Monday's report.
Timeframe Analysis:
- Short-term (Hold): Neutral reading indicates near-term momentum has faded, with the stock lacking clear directional conviction
- Medium-term (50% Buy): Moderate buy signal suggests some underlying support remains in the intermediate timeframe, though it's far from robust
- Long-term (50% Buy): Moderate buy signal reflects a balanced longer-term trend, neither decisively bullish nor bearish
Trend Characteristics: The trend is characterized as Soft in strength and Weakest in direction, indicating a fragile technical environment with limited momentum support heading into earnings.
The stock is trading at $26.30, positioned below its 5-day moving average of $26.41, below the 10-day at $26.66, below the 20-day at $26.96, below the 50-day at $27.12, and below the 100-day at $26.53. The only moving average providing support is the 200-day at $25.69, which the stock remains above. This configuration—trading beneath all shorter-term averages but above the long-term 200-day—suggests the stock is in a corrective phase within a broader uptrend.
| Period | Value | Period | Value |
|---|---|---|---|
| 5-Day MA | $26.41 | 50-Day MA | $27.12 |
| 10-Day MA | $26.66 | 100-Day MA | $26.53 |
| 20-Day MA | $26.96 | 200-Day MA | $25.69 |
The technical setup heading into earnings is cautionary rather than supportive. With the stock below all key short- and intermediate-term moving averages and technical momentum deteriorating rapidly, Pfizer lacks the technical cushion that often helps stocks weather disappointing results. The 200-day moving average at $25.69 represents the critical support level—a break below that threshold on weak earnings could trigger further selling. Conversely, a strong report that reclaims the 50-day moving average at $27.12 would signal a technical reset and potentially attract momentum buyers. The current positioning suggests the stock is vulnerable to downside if results or guidance disappoint, while a positive surprise would need to be substantial to reverse the recent technical deterioration.
